AbbVie Inc Says Adjusted Non-GAAP Earnings For Q1 Of 2024 Are Expected To Include Acquired IPR&D And Milestones Expense Of $164M On A Pre-Tax Basis; 2024 Adj Diluted EPS Guidance Range, Including Impact Of First Quarter 2024 Acquired IPR&D And Milestones Expense, Is $10.97-$11.17.
Portfolio Pulse from Benzinga Newsdesk
AbbVie Inc has announced that its adjusted non-GAAP earnings for Q1 of 2024 will include an acquired IPR&D and milestones expense of $164M on a pre-tax basis. Consequently, the company has adjusted its 2024 diluted EPS guidance range to $10.97-$11.17, factoring in the impact of these expenses.
April 03, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
AbbVie Inc has revised its 2024 earnings guidance due to a $164M pre-tax expense for acquired IPR&D and milestones, now expecting a diluted EPS of $10.97-$11.17.
The adjustment in AbbVie's earnings guidance due to the acquired IPR&D and milestones expense is significant information for investors. However, the impact on the stock price is uncertain (neutral score) as the market may have anticipated these expenses. The high relevance score is due to the direct mention of AbbVie and the specific financial figures provided. The importance is high because earnings guidance directly affects investor expectations. The confidence level is high due to the clear financial details provided, but not absolute due to the unpredictable market reaction.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100